首页 › 基金 › Eversept Partners, LP › VRDN
Eversept Partners, LP 对 VRDN 的持仓历史
VIRIDIAN THERAPEUTICS INC · 医疗保健
Eversept Partners, LP 在 Q2 2026 的 13F 申报中披露持有 VRDN(VIRIDIAN THERAPEUTICS INC)831,142 股,市值约 US$15.3M,约占其申报组合的 0.80%,在其申报持仓中市值排名第 34 位。 Eversept Partners, LP 最近 12 个申报季度中有 12 个季度披露了 VRDN 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Eversept Partners, LP 对 VRDN 的持仓演变
Eversept Partners, LP 于 Q3 2023 首次披露 VRDN 持仓:443,270 股(约 US$6.8M)。 该持仓在 Q4 2025 达到峰值 1,782,235 股,市值约 US$55.5M。 在 12 次申报中,Eversept Partners, LP 8 次增持、3 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 831,142 股、市值约 US$15.3M,环比增持 117,873 股。。 持仓曾出现大幅变动:Q4 2023 减持约 69% (随后一个季度股价下跌 20%)、Q2 2024 增持约 299% (随后一个季度股价上涨 75%)、Q1 2025 增持约 77% (随后一个季度股价上涨 4%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 443.27K | $6.80M | 新进 |
| Q4 2023 | 137.34K | $2.99M | 减持 |
| Q1 2024 | 142.07K | $2.49M | 增持 |
| Q2 2024 | 567.49K | $7.38M | 增持 |
| Q3 2024 | 691.23K | $15.73M | 增持 |
| Q4 2024 | 780.00K | $14.95M | 增持 |
| Q1 2025 | 1.38M | $18.57M | 增持 |
| Q2 2025 | 1.90M | $26.60M | 增持 |
| Q3 2025 | 1.92M | $41.53M | 增持 |
| Q4 2025 | 1.78M | $55.46M | 减持 |
| Q1 2026 | 713.27K | $13.95M | 减持 |
| Q2 2026 | 831.14K | $15.27M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 VRDN 与 13F 数据
VRDN(VIRIDIAN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 37 只申报持有 VRDN,申报仓位最大的包括:Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 VRDN 的基金
- Bellevue Group AG 6.73M 股 · $123.67M · Q2 2026
- Paradigm Biocapital Advisors LP 6.72M 股 · $123.52M · Q2 2026
- Kynam Capital Management, LP 6.45M 股 · $118.56M · Q2 2026
- Fairmount Funds Management LLC 5.09M 股 · $93.52M · Q2 2026
- Deep Track Capital, LP 3.59M 股 · $66.00M · Q2 2026
- Venrock Adviser, LLC 3.26M 股 · $59.85M · Q2 2026
- Avoro Capital Advisors LLC 2.50M 股 · $45.92M · Q2 2026
- Context Capital Management, LLC 40.75M 股 · $43.82M · Q2 2026
- BAKER BROS. ADVISORS LP 2.38M 股 · $43.78M · Q2 2026
- Caligan Partners LP 2.19M 股 · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M 股 · $39.22M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.79M 股 · $32.93M · Q2 2026
更多关于 Eversept Partners, LP
常见问题
How long has Eversept Partners, LP held VRDN?
Eversept Partners, LP has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Eversept Partners, LP's current position in VRDN?
As of Q2 2026, Eversept Partners, LP holds 831.14K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $15.27M, representing 0.80% of its reported portfolio and ranking #34.
Has Eversept Partners, LP been buying or selling VRDN?
In the latest 13F filing (Q2 2026), Eversept Partners, LP increased its position in VRDN. The position peaked in Q4 2025 at 1.78M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.